Exciting Presentation by BioAge Labs
BioAge Labs, a clinical-stage biotechnology company, is ready to present groundbreaking advancements at an upcoming conference. This event will take place at the Piper Sandler 37th Annual Healthcare Conference. Their focus on metabolic diseases, particularly those relating to aging, positions them at the forefront of biopharmaceutical innovation.
About the Conference
The event will occur over a three-day span, bringing together industry leaders and innovators. BioAge Labs’ participation reflects the increasing recognition of the importance of targeting the biological factors of aging in medical research. The company’s involvement in a fireside chat fosters a direct engagement with stakeholders and thought leaders in the healthcare space.
Leadership Participation
The fireside chat will feature Kristen Fortney, PhD, the dynamic CEO and co-founder of BioAge Labs, alongside Dov Goldstein, MD, the firm’s CFO. Scheduled for Thursday, this session will provide insights into the company's vision and ongoing projects. With strong leaders at the helm, the conversation promises to be enlightening for those interested in the intersection of biotechnology and age-related health solutions.
Access the Webcast
For those who cannot attend in person, a live webcast will be available. This opportunity allows stakeholders to stay informed about BioAge Labs' strategies and research progress. The firm will also archive the webcast, enabling broader access to their insights and discussions, further extending their reach within the investment community.
Innovative Approaches at BioAge Labs
BioAge Labs is not just about immediate presentations; it is about the future of medicine. The company is developing innovative therapeutic products targeting metabolic diseases through scientific breakthroughs in aging biology. Their lead candidate, BGE-102, is a promising small-molecule NLRP3 inhibitor, aimed at tackling obesity and cardiovascular risk factors. The ongoing Phase 1 trial of BGE-102 signifies the company's commitment to advancing health solutions.
Developments and Programs
The company is also exploring long-acting injectable methods and oral small molecule APJ agonists. These endeavors speak to BioAge Labs’ comprehensive strategy in addressing the multifaceted aspects of obesity. Their preclinical programs utilize a proprietary discovery platform that leverages data on human longevity, underscoring their cutting-edge approach to metabolic aging.
Continued Engagement with Investors
For those interested in further information about BioAge Labs, multiple channels are available for engagement. The company's commitment to transparency and communication allows investors to remain informed about ongoing projects and future developments. They encourage anyone interested in partnering or learning more to reach out through their dedicated contact points.
Contact Information
For public relations inquiries, Chris Patil is the contact point at media@bioagelabs.com. For investor relations concerns, reach out to Dov Goldstein at ir@bioagelabs.com. Partnership opportunities can be discussed at partnering@bioagelabs.com. Interested parties can find more information on their official website at https://bioagelabs.com.
Frequently Asked Questions
What is the main focus of BioAge Labs?
BioAge Labs specializes in developing therapeutics aimed at metabolic diseases by exploring the biology of human aging.
Who are the key figures presenting at the conference?
Kristen Fortney, PhD, and Dov Goldstein, MD, will represent BioAge Labs at the Piper Sandler Healthcare Conference.
How can I access the conference presentation?
A live webcast of the presentation will be available. Registration details can be found on their website.
What is BGE-102?
BGE-102 is BioAge's lead product candidate, which is a small-molecule NLRP3 inhibitor aimed at addressing obesity and cardiovascular issues.
Where can I find more information about BioAge Labs?
Information can be accessed through their official website, where ongoing projects and news updates are shared regularly.
